Drugs / [Ac 225]RTX-2358
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07156565 | Nov 2025 → Jan 2028 expected | soft tissue sarcoma | Ratio Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | \[Ac 225\]-RTX-2358 | “\[Ac 225\]-RTX-2358 is for patients with relapsed or treatment-resistant soft tissue sarcoma.” NCT07156565 ↗ |
| Route | Intravenous | “\[Ac225\]RTX-2358 will be given as an intravenous injection” NCT07156565 ↗ |